198 related articles for article (PubMed ID: 36169922)
1. Sustained Aurora Kinase B Expression Confers Resistance to PI3K Inhibition in Head and Neck Squamous Cell Carcinoma.
Shah PA; Sambandam V; Fernandez AM; Zhao H; Mazumdar T; Shen L; Wang Q; Ahmed KM; Ghosh S; Frederick MJ; Wang J; Johnson FM
Cancer Res; 2022 Dec; 82(23):4444-4456. PubMed ID: 36169922
[TBL] [Abstract][Full Text] [Related]
2. PDK1 Mediates
Sambandam V; Frederick MJ; Shen L; Tong P; Rao X; Peng S; Singh R; Mazumdar T; Huang C; Li Q; Pickering CR; Myers JN; Wang J; Johnson FM
Clin Cancer Res; 2019 Jun; 25(11):3329-3340. PubMed ID: 30770351
[TBL] [Abstract][Full Text] [Related]
3. DKK3 knockdown confers negative effects on the malignant potency of head and neck squamous cell carcinoma cells via the PI3K/Akt and MAPK signaling pathways.
Katase N; Nishimatsu SI; Yamauchi A; Yamamura M; Fujita S
Int J Oncol; 2019 Mar; 54(3):1021-1032. PubMed ID: 30569110
[TBL] [Abstract][Full Text] [Related]
4. Disruption of the RICTOR/mTORC2 complex enhances the response of head and neck squamous cell carcinoma cells to PI3K inhibition.
Ruicci KM; Plantinga P; Pinto N; Khan MI; Stecho W; Dhaliwal SS; Yoo J; Fung K; MacNeil D; Mymryk JS; Barrett JW; Howlett CJ; Nichols AC
Mol Oncol; 2019 Oct; 13(10):2160-2177. PubMed ID: 31393061
[TBL] [Abstract][Full Text] [Related]
5. ERK-TSC2 signalling in constitutively-active HRAS mutant HNSCC cells promotes resistance to PI3K inhibition.
Ruicci KM; Pinto N; Khan MI; Yoo J; Fung K; MacNeil D; Mymryk JS; Barrett JW; Nichols AC
Oral Oncol; 2018 Sep; 84():95-103. PubMed ID: 30115483
[TBL] [Abstract][Full Text] [Related]
6. Silencing novel long non-coding RNA FKBP9P1 represses malignant progression and inhibits PI3K/AKT signaling of head and neck squamous cell carcinoma in vitro.
Yang YF; Feng L; Shi Q; Ma HZ; He SZ; Hou LZ; Wang R; Fang JG
Chin Med J (Engl); 2020 Sep; 133(17):2037-2043. PubMed ID: 32769488
[TBL] [Abstract][Full Text] [Related]
7. Targeting PI3K/AKT/mTOR Signaling Pathway as a Radiosensitization in Head and Neck Squamous Cell Carcinomas.
Su YC; Lee WC; Wang CC; Yeh SA; Chen WH; Chen PJ
Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555391
[TBL] [Abstract][Full Text] [Related]
8. Campothecin suppresses cell proliferation and migration in head and neck squamous cell carcinoma by blocking RAB27A-mediated phosphatidylinositol 3 kinase (PI3K)/protein kinase B (AKT) pathway.
Zhao Y; Wang Y; Zhao L; Qu L; Zheng JH
J Physiol Pharmacol; 2024 Apr; 75(2):205-213. PubMed ID: 38736267
[TBL] [Abstract][Full Text] [Related]
9. P4HA2 contributes to head and neck squamous cell carcinoma progression and EMT through PI3K/AKT signaling pathway.
Wu YL; Liu W; Zhao T; Jin J
Med Oncol; 2024 May; 41(6):163. PubMed ID: 38777998
[TBL] [Abstract][Full Text] [Related]
10. TAM family receptors in conjunction with MAPK signalling are involved in acquired resistance to PI3Kα inhibition in head and neck squamous cell carcinoma.
Ruicci KM; Meens J; Plantinga P; Stecho W; Pinto N; Yoo J; Fung K; MacNeil D; Mymryk JS; Barrett JW; Howlett CJ; Boutros PC; Ailles L; Nichols AC
J Exp Clin Cancer Res; 2020 Oct; 39(1):217. PubMed ID: 33059733
[TBL] [Abstract][Full Text] [Related]
11. Recent insights in the PI3K/Akt pathway as a promising therapeutic target in combination with EGFR-targeting agents to treat head and neck squamous cell carcinoma.
Zaryouh H; De Pauw I; Baysal H; Peeters M; Vermorken JB; Lardon F; Wouters A
Med Res Rev; 2022 Jan; 42(1):112-155. PubMed ID: 33928670
[TBL] [Abstract][Full Text] [Related]
12. A positive feedback loop involving EGFR/Akt/mTORC1 and IKK/NF-kB regulates head and neck squamous cell carcinoma proliferation.
Li Z; Yang Z; Passaniti A; Lapidus RG; Liu X; Cullen KJ; Dan HC
Oncotarget; 2016 May; 7(22):31892-906. PubMed ID: 26895469
[TBL] [Abstract][Full Text] [Related]
13. Targeting EGFR-PI3K-AKT-mTOR signaling enhances radiosensitivity in head and neck squamous cell carcinoma.
Horn D; Hess J; Freier K; Hoffmann J; Freudlsperger C
Expert Opin Ther Targets; 2015 Jun; 19(6):795-805. PubMed ID: 25652792
[TBL] [Abstract][Full Text] [Related]
14. Risk SNP-mediated LINC01614 upregulation drives head and neck squamous cell carcinoma progression via PI3K/AKT signaling pathway.
Hou Y; Zhou M; Li Y; Tian T; Sun X; Chen M; Xu W; Lu M
Mol Carcinog; 2022 Aug; 61(8):797-811. PubMed ID: 35687049
[TBL] [Abstract][Full Text] [Related]
15. Focal overexpression of CEACAM6 contributes to enhanced tumourigenesis in head and neck cancer via suppression of apoptosis.
Cameron S; de Long LM; Hazar-Rethinam M; Topkas E; Endo-Munoz L; Cumming A; Gannon O; Guminski A; Saunders N
Mol Cancer; 2012 Sep; 11():74. PubMed ID: 23021083
[TBL] [Abstract][Full Text] [Related]
16. AKT3 is a key regulator of head and neck squamous cell carcinoma.
Takahashi H; Rokudai S; Kawabata-Iwakawa R; Sakakura K; Oyama T; Nishiyama M; Chikamatsu K
Cancer Sci; 2021 Jun; 112(6):2325-2334. PubMed ID: 33811778
[TBL] [Abstract][Full Text] [Related]
17. MEK Inhibitor PD-0325901 Overcomes Resistance to PI3K/mTOR Inhibitor PF-5212384 and Potentiates Antitumor Effects in Human Head and Neck Squamous Cell Carcinoma.
Mohan S; Vander Broek R; Shah S; Eytan DF; Pierce ML; Carlson SG; Coupar JF; Zhang J; Cheng H; Chen Z; Van Waes C
Clin Cancer Res; 2015 Sep; 21(17):3946-56. PubMed ID: 25977343
[TBL] [Abstract][Full Text] [Related]
18. Knockdown of HPIP Inhibits the Proliferation and Invasion of Head-and-Neck Squamous Cell Carcinoma Cells by Regulating PI3K/Akt Signaling Pathway.
Chen Y; Zhao R; Zhao Q; Shao Y; Zhang S
Oncol Res; 2016; 24(3):153-60. PubMed ID: 27458096
[TBL] [Abstract][Full Text] [Related]
19. The PI3K/Akt/mTORC signaling axis in head and neck squamous cell carcinoma: Possibilities for therapeutic interventions either as single agents or in combination with conventional therapies.
Akbari Dilmaghani N; Safaroghli-Azar A; Pourbagheri-Sigaroodi A; Bashash D
IUBMB Life; 2021 Apr; 73(4):618-642. PubMed ID: 33476088
[TBL] [Abstract][Full Text] [Related]
20. The effect of medicarpin on PTEN/AKT signal pathway in head and neck squamous cell carcinoma.
Yiğin AK; Donmez H; Hitit M; Seven S; Eser N; Kurar E; Seven M
J Cancer Res Ther; 2022; 18(1):180-184. PubMed ID: 35381781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
